Menu

Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer

Top Stories Feed·Vandana Singh·about 2 hours ago
#xX2chmzR
#benzinga#merck#phase#trofuse#trop2
Long article (336 words) — no AI summary yet.
Reading 0:00
15s threshold

Merck & Co. Inc. (NYSE:MRK) on Friday announced that its pivotal Phase 3 TroFuse-015 trial met its primary endpoint of overall survival (OS).

Evaluating sacituzumab tirumotecan (sac-TMT), the trial marks the first time a TROP2-directed ADC improved OS in a global Phase 3 study for locally advanced unresectable or metastatic gastroesophageal adenocarcinoma patients who received two or more prior lines of systemic therapy.

sac-TMT is an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech.

Read Also: Merck One of Top Large-Cap Biopharma Picks-Analyst

Trial Efficacy And Safety Results

At final analysis, sac-TMT delivered a statistically significant and clinically meaningful OS improvement compared to treatment of physician’s choice (TPC), which consisted of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel.

Researchers observed generally consistent results across patient subgroups regardless of TROP2 expression status.

However, sac-TMT did not meet its…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.